On Target Laboratories, LLC

Quick facts

Phase 3 pipeline

• OTL38 for Injection · Oncology
  OTL38 is a folate receptor alpha-targeted immunoconjugate that delivers a cytotoxic payload to cancer cells expressing folate receptor alpha.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• On Target Laboratories, LLC portfolio CI brief
• On Target Laboratories, LLC pipeline updates RSS